RAPS Expands to Taiwan
RAPS announced a new chapter in Taiwan, which is its first in Asia.
The Regulatory Affairs Professionals Society (RAPS) announced a new chapter in Taiwan, which is its first in Asia. The Taiwan Chapter, which started as an affiliate, has expanded to an official chapter, allowing it to offer additional resources and opportunities to the regulatory community in Taiwan.
RAPS has made a series of moves expanding its presence in Asia, including the opening of two new offices in Asia—a Pan-Asia office in Singapore, serving the entire Asia-Pacific region, and another in Shanghai, serving the regulatory community in China.
Taiwan Chapter membership is open to all who reside in Taiwan and are involved in regulatory affairs, quality or other functions related to healthcare product regulation. For information about how to join and membership benefits, contact the RAPS Taiwan Chapter via the web page at http://www.raps-in-taiwan.org.tw.
Read the full release here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
